Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria

Key Points

• Neuroprotective drugs improved outcomes in experimental cerebral malaria, indicating therapy potential.
• Notable improvements were observed in survival rates and neurological function in treated models.
• Analysis of neuroprotective drug efficacy, with a focus on adjunct therapy use in cerebral malaria cases.
• Highlights the need for further investigation into adjunct therapies for better clinical outcomes.